文献速递流行病学与生物统计基础与转化研究

SGLT2抑制剂与血红蛋白、铁代谢及红细胞生成标志物水平:随机临床试验的系统综述与Meta分析

Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
PubMed 文献 · JAMA · 2026-10-24

结果显示SGLT2抑制剂使血红蛋白较基线变化0.55 g/dL、血细胞比容变化2.17%,均显著高于对照组,促红细胞生成素升高而转铁蛋白饱和度降低。作者指出这些变化的临床意义尚不清楚。

要点

  • SGLT2抑制剂较对照使血红蛋白净差增加0.60 g/dL(95%CI 0.55-0.66),血细胞比容净差增加2.36%(95%CI 2.19-2.52)。
  • 促红细胞生成素较对照净差升高2.11 mIU/mL(95%CI 0.5-3.71),转铁蛋白饱和度净差降低0.84%(95%CI -1.21至-0.47)。
  • 上述血液学变化幅度较小,其临床意义尚不明确。

核心结论

  • 与对照相比,SGLT2抑制剂使用与血红蛋白和血细胞比容出现小幅但具有统计学意义的升高相关。
  • 这些变化的临床意义尚不清楚。

研究设计与样本

  • 系统综述与随机效应Meta分析,检索PubMed、Web of Science和Cochrane CENTRAL自建库至2026年7月22日。
  • 研究对象为患有心血管疾病、糖尿病、心力衰竭和/或慢性肾脏病中至少一种疾病的患者。
  • 主要结局为血红蛋白和血细胞比容变化,次要结局包括红细胞浓度、促红细胞生成素及铁代谢指标。

主要发现

  • SGLT2抑制剂组血红蛋白自基线变化0.55 g/dL(95%CI 0.49-0.61;P<.001),对照组变化-0.08 g/dL(95%CI -0.13至-0.03;P=.003),组间差异0.60 g/dL(95%CI 0.55-0.66;P<.001)。
  • SGLT2抑制剂组血细胞比容自基线变化2.17%(95%CI 1.95%-2.39%;P<.001),对照组变化-0.13%(95%CI -0.28%至0.01%;P=.07),组间差异2.36%(95%CI 2.19%-2.52%;P<.001)。
  • 6项次要结局中4项与SGLT2抑制剂显著相关,包括促红细胞生成素升高(SGLT2抑制剂组2.35 mIU/mL vs 对照组0.04 mIU/mL;差异2.11 mIU/mL,95%CI 0.5-3.71;P=.01)。
  • 转铁蛋白饱和度降低(SGLT2抑制剂组-2.2% vs 对照组-0.10%;差异-0.84%,95%CI -1.21%至-0.47%;P<.001)。

关键数值与推荐

  • 基线平均血红蛋白13.6 g/dL(SD 1.5),基线平均血细胞比容41.5%(SD 4.9)。
  • 血红蛋白组间净差0.60 g/dL(95%CI 0.55-0.66;P<.001),血细胞比容组间净差2.36%(95%CI 2.19-2.52;P<.001)。
  • 促红细胞生成素组间净差2.11 mIU/mL(95%CI 0.5-3.71;P=.01)。
  • 转铁蛋白饱和度组间净差-0.84%(95%CI -1.21%至-0.47%;P<.001)。

临床怎么用

  • 临床使用SGLT2抑制剂时可预期血红蛋白和血细胞比容小幅升高,解读血常规变化时需考虑这一药物效应。
  • 对合并贫血或铁代谢异常的患者,SGLT2抑制剂对促红细胞生成素和转铁蛋白饱和度的影响可供个体化评估参考。
  • 上述血液学变化的临床意义尚不明确,不应仅据此改变SGLT2抑制剂的治疗决策。

局限性

  • 原文未报告纳入试验的偏倚风险、异质性及发表偏倚评估结果。
  • 中位随访24周,长期血液学效应尚不明确。
  • 活性对照试验仅7项(3335例),与安慰剂对照相比证据有限。
  • 作者指出这些发现的临床意义尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In randomized clinical trials, sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with increased hemoglobin and hematocrit compared with placebo. However, the magnitude and importance of this association remain unclear. OBJECTIVE: To evaluate the associations between SGLT2 inhibitor use and levels of hemoglobin, hematocrit, and markers of iron metabolism and erythropoiesis compared with placebo or active comparator. DATA SOURCES: PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to July 22, 2026. STUDY SELECTION: Randomized, double-masked clinical trials comparing SGLT2 inhibitor use with placebo or active comparators in patients with 1 or more of the following conditions: cardiovascular disease, diabetes, heart failure, and chronic kidney disease. DATA EXTRACTION AND SYNTHESIS: Three reviewers independently extracted data and results were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Primary outcomes were changes in hemoglobin and hematocrit. Secondary outcomes were changes in red blood cell concentration, erythropoietin (EPO), and iron measures (serum iron, ferritin, transferrin saturation, and hepcidin). RESULTS: A total of 85 randomized clinical trials were analyzed (median [IQR] duration, 24 [12-32] weeks), including 70 543 participants (mean [SD] age, 62.4 [9.4] years; 25 334 female [35.9%]). Mean (SD) baseline hemoglobin was 13.6 (1.5) g/dL; baseline hematocrit was 41.5% (4.9). Seventy-eight clinical trials (67 208 participants) compared SGLT2 inhibitors with placebo, and 7 clinical trials (3335 participants) used active comparators, most commonly sitagliptin (2 trials [1158 participants]). From baseline to follow-up, hemoglobin changed by 0.55 g/dL (95% CI, 0.49 to 0.61 g/dL; P < .001) in the SGLT2 inhibitor group, and -0.08 g/dL (95% CI, -0.13 to -0.03 g/dL; P = .003) in the control group (difference, 0.60 g/dL; 95% CI, 0.55 to 0.66 g/dL; P < .001). From baseline to follow-up, hematocrit changed by 2.17% (95% CI, 1.95% to 2.39%; P < .001) in the SGLT2 inhibitor group and -0.13% (95% CI, -0.28% to 0.01%; P = .07) in the control group (difference, 2.36%; 95% CI, 2.19% to 2.52%; P < .001). Of the 6 secondary outcomes, 4 showed significant associations with SGLT2 inhibitors, including increased EPO (2.35 mIU/mL in SGLT2 inhibitor group vs 0.04 mIU/mL in control group; difference, 2.11 mIU/mL [95% CI, 0.5-3.71 mIU/mL]; P = .01) and decreased transferrin saturation (-2.2% in SGLT2 inhibitor group vs -0.10% in control group; difference, -0.84% [95% CI, -1.21% to -0.47%]; P < .001). CONCLUSIONS AND RELEVANCE: In a meta-analysis of randomized clinical trials, compared with control, SGLT2 inhibitor use was associated with small statistically significant increases in hemoglobin and hematocrit levels. The clinical significance of these findings is unclear.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Yang Y, Yang C, Wang Y, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. JAMA. 2026. PMID: 42925557. doi:10.1001/jama.2026.19921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。